SGT-510

SGT-510 is an investigational **topical roflumilast** product candidate developed by Sol-Gel Technologies for **plaque psoriasis** and potentially other dermatologic conditions. Roflumilast is a **small-molecule phosphodiesterase 4 inhibitor** that is intended to reduce inflammatory signaling by increasing intracellular cyclic AMP in inflammatory cells and skin tissue. Public company materials describe SGT-510 as a proprietary topical formulation designed to improve efficacy versus conventionally formulated roflumilast cream in preclinical psoriasis models. The program appears to have remained in the preclinical or very early development stage and was later reported by the company as suspended in favor of prioritizing other pipeline assets.

Brand names

Zoryve

Other names

topical roflumilastroflumilast